Charles River Laboratories has snapped up British CRO KWS BioTest for £15 million ($20 million), enhancing its offerings in immuno-oncology and inflammatory and infectious diseases.
KWS specializes in offering in vitro and in vivo testing services in the larger area of immunology, including target identification and validation, lead optimization, in vivo disease models and clinical sample analysis.
“The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system,” said Charles River chairman, president and CEO James Foster, in a statement.
Recent research progress in immuno-oncology, most notably checkpoint inhibitors and the recent CAR-T therapies, have clearly sparked growing interest from biopharma companies as developers and CROs as service supporters. The KWS acquisition follows two other CRO consolidations with a focus on immunology/immuno-oncology: Cancer Genetics’ $12 million deal for Australian CRO vivoPharm last August and Concept Life Sciences’ November purchase of Aquila BioMedical.
Charles River itself has also been building up its oncology offerings. It recently formed a collaboration with InSphero to build in vitro 3D tumor microtissues from patient-derived xenographs (PDXs) for more accurate evaluation of cancer treatments. It also added more molecular characteristics to its library of PDXs back in May.
The CRO giant also pledged an additional £3 million for KWS based on its future performance and said the transaction wasn’t expected to substantially affect its 2018 results.
By Angus Liu
Source: Fierce Biotech
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.